Whats unclear is how regulators are allowing this, PhRMA said in a Feb
Clinical trials back this up: the STEP trials showed an average weight reduction of around 15% with Semaglutide, while the SURMOUNT trials reported up to 20% with Tirzepatide
GLP-1 medications solve this by using modified versions of the hormone that resist enzymatic breakdown, maintaining elevated levels for days or even a full week depending on the formulation
These include SGLT2 inhibitors, optimised insulin regimens, structured education programs and targeted lifestyle support
It also helps to reframe what a plateau even is
Detailed patient-level data: Truveta Data includes biometric data (such as weights), dispense data, lab values (such as A1C levels), and SDOH